Spremljaj
Seth M. Pollack
Seth M. Pollack
Preverjeni e-poštni naslov na northwestern.edu - Domača stran
Naslov
Navedeno
Navedeno
Leto
T‐cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death‐ligand 1 expression in patients with soft tissue sarcomas
SM Pollack, Q He, JH Yearley, R Emerson, M Vignali, Y Zhang, ...
Cancer 123 (17), 3291-3304, 2017
2602017
Soft tissue sarcoma, version 2.2022, NCCN clinical practice guidelines in oncology
M von Mehren, JM Kane, M Agulnik, MM Bui, J Carr-Ascher, E Choy, ...
Journal of the National Comprehensive Cancer Network 20 (7), 815-833, 2022
2392022
Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer
YD Seo, X Jiang, KM Sullivan, FG Jalikis, KS Smythe, A Abbasi, M Vignali, ...
Clinical Cancer Research 25 (13), 3934-3945, 2019
2032019
NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma
SM Pollack, AA Jungbluth, BL Hoch, EA Farrar, M Bleakley, DJ Schneider, ...
Cancer 118 (18), 4564-4570, 2012
1442012
Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment
KC Shibuya, VK Goel, W Xiong, JG Sham, SM Pollack, AM Leahy, ...
PloS one 9 (5), e96565, 2014
1432014
Systemic interferon-γ increases MHC class I expression and T-cell infiltration in cold tumors: results of a phase 0 clinical trial
S Zhang, K Kohli, RG Black, L Yao, SM Spadinger, Q He, VG Pillarisetty, ...
Cancer immunology research 7 (8), 1237-1243, 2019
1372019
Novel therapeutic approaches in chondrosarcoma
G Polychronidou, V Karavasilis, SM Pollack, PH Huang, A Lee, RL Jones
Future Oncology 13 (7), 637-648, 2017
1292017
Assessment of doxorubicin and pembrolizumab in patients with advanced anthracycline-naive sarcoma: a phase 1/2 nonrandomized clinical trial
SM Pollack, MW Redman, KK Baker, MJ Wagner, BA Schroeder, ...
JAMA oncology 6 (11), 1778-1782, 2020
1172020
Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone
E Palmerini, RL Jones, E Marchesi, A Paioli, M Cesari, A Longhi, ...
BMC cancer 16, 1-8, 2016
1142016
Emerging targeted and immune-based therapies in sarcoma
SM Pollack, M Ingham, MB Spraker, GK Schwartz
Journal of Clinical Oncology 36 (2), 125-135, 2018
902018
NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine
SM Pollack, Y Li, MJ Blaisdell, EA Farrar, J Chou, BL Hoch, ET Loggers, ...
PloS one 7 (2), e32165, 2012
882012
First-in-class, first-in-human study evaluating LV305, a dendritic-cell tropic lentiviral vector, in sarcoma and other solid tumors expressing NY-ESO-1
N Somaiah, MS Block, JW Kim, GI Shapiro, KT Do, P Hwu, JP Eder, ...
Clinical Cancer Research 25 (19), 5808-5817, 2019
862019
A contemporary large single-institution evaluation of resected retroperitoneal sarcoma
PJ Bremjit, RL Jones, X Chai, G Kane, ET Rodler, ET Loggers, SM Pollack, ...
Annals of surgical oncology 21, 2150-2158, 2014
852014
More than 50 subtypes of soft tissue sarcoma: paving the path for histology-driven treatments
D Katz, E Palmerini, SM Pollack
American Society of Clinical Oncology Educational Book 38, 925-938, 2018
822018
Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8+ T cells
SM Pollack, RL Jones, EA Farrar, IP Lai, SM Lee, J Cao, VG Pillarisetty, ...
Journal for immunotherapy of cancer 2, 1-10, 2014
802014
Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial
SP D'Angelo, DM Araujo, ARA Razak, M Agulnik, S Attia, JY Blay, ...
The Lancet 403 (10435), 1460-1471, 2024
742024
MRI radiomic features are independently associated with overall survival in soft tissue sarcoma
MB Spraker, LS Wootton, DS Hippe, KC Ball, JC Peeken, MW Macomber, ...
Advances in radiation oncology 4 (2), 413-421, 2019
712019
NCCN Guidelines® insights: gastrointestinal stromal tumors, version 2.2022: featured updates to the NCCN guidelines
M von Mehren, JM Kane, RF Riedel, JK Sicklick, SM Pollack, M Agulnik, ...
Journal of the National Comprehensive Cancer Network 20 (11), 1204-1214, 2022
662022
The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients
SM Pollack
Expert review of vaccines 17 (2), 107-114, 2018
642018
First-in-human treatment with a dendritic cell-targeting lentiviral vector-expressing NY-ESO-1, LV305, induces deep, durable response in refractory metastatic synovial sarcoma …
SM Pollack, H Lu, S Gnjatic, N Somaiah, RB O’Malley, RL Jones, FJ Hsu, ...
Journal of immunotherapy 40 (8), 302-306, 2017
632017
Sistem trenutno ne more izvesti postopka. Poskusite znova pozneje.
Članki 1–20